03Care Catalogue
Women's Health
Premium Clinical Services
Browse our comprehensive clinical tests and treatments in Dubai.
Explore Women's Health17
NIPT - Basic (5 chromosomes)
The Non-Invasive Prenatal Testing (NIPT) - Basic analyzes the presence of chromosomal abnormalities for five chromosomes, offering expectant parents vital insights into their baby's health.
NIPT - Advance (All 23 chromosomes)
Non-Invasive Prenatal Testing (NIPT) is a revolutionary screening test that assesses the risk of chromosomal abnormalities in the fetus through a simple blood test from the mother. It provides accurate results for all 23 chromosomes, including conditions like Down syndrome.
"NIPT Advance plus (All chromosomes + microdeletion)
The NIPT Advance Plus test analyzes all chromosomes for potential genetic abnormalities, including microdeletions, offering early insights into the health of the fetus. It is a non-invasive procedure performed using a simple blood sample from the mother.
Maternal screen-2nd Trimester Triple marker test
The Maternal screen-2nd Trimester Triple marker test is a blood test used to assess the risk of certain fetal chromosomal abnormalities. It measures three specific markers in the blood during the second trimester of pregnancy.
HPV Genotyping PCR
HPV Genotyping PCR is a molecular test that detects the presence of high-risk strains of the Human Papillomavirus (HPV) in a sample. It is crucial for assessing cervical cancer risk and guiding follow-up care.
PAP Smear Test
A PAP Smear Test is a screening procedure for cervical cancer, where a sample of cells is collected from the cervix to be examined for abnormalities.
HPV Genotyping PCR+PAP SMEAR
The HPV Genotyping PCR+PAP SMEAR is a comprehensive screening test that detects the presence of high-risk HPV types which can lead to cervical cancer, alongside a pap smear to assess any cellular changes.
Thombophilia Panel
The Thrombophilia Panel is a comprehensive blood test that evaluates the risk of developing abnormal blood clots. It measures various genetic and acquired factors that can increase the likelihood of thrombosis.
Factor V Leiden Mutation (G1691A), QUALITATIVE
The Factor V Leiden Mutation (G1691A) test detects the presence of a genetic mutation that increases the risk of thrombosis. This qualitative test provides crucial information for patients with a family history of blood clots.
Maternal screen-1st Trimester Dual Marker test
The Maternal Screen - 1st Trimester Dual Marker test screens for chromosomal abnormalities in the fetus by measuring the levels of specific biomarkers in the mother's blood. This non-invasive test offers critical early insight into potential risks.
Y Chromosome Microdeletion (16 Mutations)
The Y Chromosome Microdeletion (16 Mutations) test identifies specific microdeletions in the Y chromosome that can affect male fertility and development. This genetic test is essential for understanding underlying male reproductive issues.
Factor II Prothrombin Mutation (G20210A), QUALITATIVE
The Factor II Prothrombin Mutation (G20210A) test is a qualitative genetic test that assesses the presence of the specific mutation associated with increased risk of thrombosis. This mutation can lead to abnormal blood clotting, making it crucial for individuals with a family history of clotting disorders.
MTHFR (C677T & 1298C) GENE MUTATION, QUALITATIVE
The MTHFR gene mutation test analyzes genetic variations related to methylation processes in the body. This qualitative test is crucial for understanding potential health implications associated with the MTHFR gene.
NGS COUPLE CARRIER SCREENING
NGS Couple Carrier Screening is a comprehensive genetic test that screens both partners for inherited genetic conditions. It helps identify potential risks of passing on certain genetic disorders to offspring.
NGS COUPLE CARRIER SCREENING + DMD+SMA
NGS Couple Carrier Screening is a genetic test that assesses couples for carrier status of genetic diseases such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). This screening helps in understanding the risk of passing genetic disorders to offspring.
BRCA1/2 germline mutation detection by NGS + deletion/duplication detection by MPLA
The BRCA1/2 germline mutation detection test utilizes next-generation sequencing (NGS) to identify mutations in the BRCA1 and BRCA2 genes, which are linked to an increased risk of breast and ovarian cancer. The test also includes deletion and duplication detection through multiplex ligation-dependent probe amplification (MPLA) for a comprehensive analysis.
Comprehensive Hereditary Cancer Panel (154 genes)
The Comprehensive Hereditary Cancer Panel assesses 154 genes associated with inherited cancer risk, helping to identify genetic predispositions to various cancers in individuals and families.